Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
multiple myeloma
Biotech
Takeda drops cancer candidates amid shifting treatment landscape
Takeda axed a midphase immunocytokine and three early-stage CAR-T cell therapy prospects from its R&D pipeline.
Nick Paul Taylor
Feb 2, 2024 5:33am
Regeneron's 'best-in-class' myeloma drug spurs 100% side effects
Dec 7, 2023 7:00am
C4 culls phase 1/2 cancer program after efficacy fail
Nov 1, 2023 11:29am
AbbVie drops Harpoon’s BCMA drug, ending dream of $200M payday
Sep 14, 2023 10:21am
BMS posts 'modest' survival data on heir to Revlimid, Pomalyst
Aug 30, 2023 5:00pm
HaemaLogix's myeloma drug boosts responses in Revlimid combo
Jun 29, 2023 9:10am